CTMX250117C3000
- 0.00
- 0.000.00%
CytomX Newsroom
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
CytomX Heading Into 'Major Catalyst Year,' Says JonesResearch
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
Here's Why Agios Stock Plummeted More Than 20% on Monday
Improved Revenues Required Before CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock's 28% Jump Looks Justified
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $3.25
CytomX Therapeutics Price Target Lowered to $3.25 From $3.50 at Piper Sandler
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript Summary
12 Health Care Stocks Moving In Friday's Pre-Market Session
Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5
CytomX Therapeutics (CTMX) Receives a Buy From Barclays
CytomX Therapeutics: Q3 Earnings Snapshot
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q3 Revenue $33.4M
CytomX GAAP EPS of $0.07 Beats by $0.23, Revenue of $33.4M Beats by $16.3M
CytomX | 8-K: CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | CytomX Therapeutics Q3 Net Income USD 5.736 Million
CytomX Therapeutics 3Q EPS 7c >CTMX
CytomX | 10-Q: Q3 2024 Earnings Report